Kornimate/medical-research-clean huggingface dataset:
the perceptual experience of argus ii users

Conditions: Retinitis Pigmentosa

Summary: this basic experimental studies involving humans (besh) study investigates phosphene perception and performance factors in blind participants implanted with the argus ii retinal prosthesis system. using paired-electrode stimulation, we analyze how phosphene shape and number are influenced by neuroanatomical factors, stimulus parameters, and spatial offsets. additionally, we examine the causes of high current thresholds and limited spatial resolution, which impede pattern vision in argus ii devices. this research aims to provide insights for optimizing stimulation strategies and improving retinal prosthesis design.

this study focuses on two experiments involving blind participants implanted with the argus ii retinal prosthesis: experiment 1: paired-electrode phosphene perception the study retrospectively analyzes 3548 phosphene drawings made by three participants. we investigate the impact of single- and paired-electrode stimulation on phosphene shape (area, perimeter, major/minor axis length) and the number of perceived phosphenes. neuroanatomical parameters, including electrode-retina distance, electrode-fovea distance, and electrode-electrode distance (both along-axon and between-axon), are correlated with these outcomes. statistical analyses include linear regression and partial correlation to examine the relationship between stimulation parameters and phosphene perception. experiment 2: performance factors in argus ii prostheses this study explores the factors contributing to high current amplitude thresholds and poor spatial resolution in three participants. we measure current amplitude thresholds and two-point discrimination (the ability to distinguish stimulation on one versus two electrodes). data from psychophysical experiments and simulations are analyzed to identify the roles of axonal stimulation, electrode lift, and retinal damage in limiting device performance. these experiments aim to advance the understanding of epiretinal stimulation and inform the development of future retinal prostheses with improved spatial resolution and sensitivity.

Eligibility criteria:
inclusion criteria: * subject must be at least 25 years of age; * subject has been implanted with the argus ii system; * subject's eye has healed from surgery and the surgeon has cleared the subject for programming; * subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback); * subject is willing to conduct psychophysics testing up to 4-6 hours per day of testing on 3-5 consecutive days; * subject is capable of understanding patient information materials and giving written informed consent; * subject is able to walk unassisted. exclusion criteria: * subject is unwilling or unable to travel to testing facility for at least 3 days of testing within a one-week timeframe; * sighted controls: subject has a history of motion sickness or flicker vertigo * subject does not speak english; * subject has language or hearing impairment
diagnostic value of the biofire®in community acquired pneumonia

Conditions: Pneumonia

Summary: this study aimed to determine the impact value of the biofire filmarray pneumonia panel compared to conventional sputum culture in critically ill patients with pneumonia.

the biofire® filmarray pneumonia panel (bfpp) emerges as a promising candidate for a rapid and multifaceted diagnostic approach. this study compare the diagnostic accuracy, turnaround time, and impact on antibiotic management decisions of bfpp versus conventional sputum culture in critically ill patients admitted to the icu with suspected pneumonia.

Eligibility criteria:
inclusion criteria: * patients admitted to the icu with community acquired pneumonia exclusion criteria: * age less than 18 years old. * end stage malignant patients, * patients admitted to the icu with acute lung injury (ali). * patients admitted to the icu with acute respiratory distress syndrome (ards). * patients with radiological findings suggesting atypical pneumonia. * immunocompromised as defined by hiv/aids, known immunodeficiency, chronic steroids \> 20mg/day prednisone equivalent, other immunosuppressants. * solid organ or bone marrow transplant patients, cystic fibrosis. * unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete the study requirements.
post covid-19 syndrome and the gut-lung axis

Conditions: Covid19

Summary: the outbreak of the novel coronavirus (sars-cov-2)-infected disease (covid-19) began in december 2019, spread throughout china in early 2020 and developed as a pandemic thereafter. based on current knowledge, covid-19 infection causes mild to moderate respiratory and gastrointestinal symptoms in the majority of patients. in a smaller percentage severe disease courses are observed, often with the need of hospitalization and intensive care treatment. apparently, symptoms can persist for relatively long time after viral clearance, suggesting the existence of a "post-covid" syndrome. a study from the uk identified fatigue, breathlessness and psychosocial stress as common symptoms after discharge from the hospital. covid-19 infection is frequently characterized by a hyperinflammatory phenotype and a cytokine storm. the covid-19 cytokine storm is characterised by rapid proliferation and hyperactivation of t cells, macrophages, mast cells, neutrophil granulocytes and natural killer cells, and the overproduction of inflammatory cytokines and chemical mediators released by immune or nonimmune cells. early data also suggest that even if symptoms are just 'mild to moderate' during the acute infection, fibrotic lung damage develops in some patients. this may lead to long-term pulmonary complications for a subset of patients. the mechanisms for post-covid pulmonary fibrosis are still unclear: inflammation triggering fibrosis, epithelial and endothelial injury with inadequate fibroproliferation and vascular damage are considered to be possible mechanisms. a potential therapeutic target in ameliorating post-covid symptoms could be the gut microbiome. gut microbiome alterations have been described in covid-19. the gut-lung axis as a link between dysbiosis, barrier dysfunction, translocation of bacterial products and hyperinflammation has been proposed as a potential therapeutic target. probiotics have been proposed to be a possible modulator of the deranged gut-lung axis in covid-disease and post-covid syndrome. currently 11 studies are registered in clinicaltrials.gov for treatment of acute covid disease and prevention of the disease (including one study from graz), but no study related to post-covid syndrome could be found. therefore, it is currently unclear, which clinical, immune system or microbiome related biomarker would be the best to study the effect of a microbiome-based intervention in post-covid syndrome.


Eligibility criteria:
inclusion criteria: * 18 years or older * covid-19 infection with severe disease defined within the last 12 months (defined as one or more of the following: hospitalization, need for oxygen supply, need for intensive care treatment, need for specific treatment of covid disease, antibiotic treatment) * subjective presence of residual symptoms of covid disease or no residual symptoms of covid disease (controls) * informed consent exclusion criteria: * continuous probiotic treatment in the last 4 weeks before inclusion * pre-existing lung diseases
study of pf-06940434 in patients with advanced or metastatic solid tumors.

Conditions: Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Lung Squamous Cell Carcinoma; Pancreatic Cancer; Bile Duct Cancer; Endometrial Cancer; Melanoma Cancer; Urothelial Cancer

Summary: open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of pf-06940434 (integrin alpha-v/beta-8 antagonist) in patients with scchn (squamous cell carcinoma of the head and neck), renal cell carcinoma (rcc - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. this study contains two parts, single agent dose escalation (part 1a), dose finding of pf 06940434 in combination with anti-pd-1 (part 1b) and dose expansion (part 2). part 2 dose combination expansion will enroll participants into 3 cohorts at doses determined from part 1b in order to further evaluate the safety of pf-06940434 in combination with anti-pd-1.


Eligibility criteria:
inclusion criteria: - histological or cytological diagnosis of scchn, rcc (clear cell and papillary cell), ovarian, gastric, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma, or urothelial cancer. part 2: * arm a scchn: * primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx. * pdl-1 expression positive and cps ≥1. no prior systemic therapy administered in the recurrent or metastatic setting (except for systemic therapy given as part of a multimodal treatment for locally advanced disease). * arm b rcc (clear cell): * 1 or 2 prior lines of therapy including pd-l1/pd-1 immunotherapy in combination or sequentially with antiangiogenic directed treatment * adequate bone marrow, kidney and liver function. * performance status of 0 or 1. exclusion criteria: * participant disease status is suitable for local therapy administered with curative intent. * hypertension that cannot be controlled by medications. * active or prior autoimmune disease * active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) hepatitis b, hepatitis c, and known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
a study to describe pediatric influenza vaccine coverage

Conditions: Healthy

Summary: the purpose of this study is to describe flu vaccine coverage in children under 18 years of age and to examine correlations between in-office flu vaccine coverage and the use of various tactics to increase vaccine coverage.

to describe influenza vaccine coverage in children less than 18 years of age in practicing pediatricians' offices and family medicine physicians' offices and to examine correlations between in-office influenza vaccine coverage and the use of various tactics to increase vaccine coverage.

Eligibility criteria:
sites selected to participate were required to be able to accurately identify the number of patients under their care by age group and provide influenza vaccine at their location.
rationalisation of polypharmacy by the geriatric consultation team

Conditions: Iatrogenic Disease

Summary: polypharmacy is a common problem in elderly, leading among others to increased adverse drug events. the aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team using the rasp (rationalisation of drugs on admission by an adjusted stopp\*-list in older patients) list could reduce inappropriate prescribing for elderly admitted patients, admitted to non-geriatric departments. (\* = screening tool of older persons' potentially inappropriate prescriptions)

polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events . the aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (gct) using the rasp (rationalisation of drugs on admission by an adjusted stopp-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. the gct could offer the ideal format to deliver the intervention to a broad older hospitalised population.

Eligibility criteria:
inclusion criteria: * admitted to a non-geriatric ward * 75 years or older * dutch speaking * consultation by the gct exclusion criteria: * end-of-life * no drugs on admission

Keywords: frailty geriatric, elderly polypharmacy
captain-ad: clinical study of amorepacific's trpv1 antagonist in atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a phase iii study to investigate the safety and efficacy of pac-14028 cream in atopic dermatitis patients.

pac-14028 cream 1.0% or placebo will be treated to mild to moderate atopic dermatitis patients twice daily for 8 weeks.

Eligibility criteria:
inclusion criteria: * male and female patients aged 12 - 70 years. * who was diagnosed with atopic dermatitis according to haniffin and rajka criteria. * whose affected tbsa is over 5% and below 30%, and iga score is 2 (mild) to 3 (moderate). * who voluntarily agreed to participate in the study and signed an informed consent form. exclusion criteria: * who has skin diseases other than atopic dermatitis or scar in the affected area which can affect the study, determined by the study investigators. * who has clinically significant medical history or diseases involving liver, kidney, neurological system, psychical disorder that can affect study results. * who has used systemic steroids, antibiotics, immunosuppressants, or received phototherapy within 28 days before study drug administration. * who has used topical steroids, topical calcineurin inhibitors or antibiotics to treat atopic dermatitis within 14 days before study drug administration. * who has used or is expected to inevitably use prohibited concomitant medications during the study. * women who is pregnant /breast-feeding, or who has childbearing potential and does not use available contraceptives. * who has dosed other study medications within 30 days before screening. * who is determined ineligible for study participation by investigators for any other reasons.
e-five registry: a world-wide registry with the endeavor zotarolimus eluting coronary stent

Conditions: Coronary Artery Disease

Summary: the safety and efficacy of the endeavor(tm) abt-578 eluting coronary stent system has been assessed in a series of studies. the stent is coated with a proprietary drug compound that is designed to reduce restenosis. this prospective multi-center study has been initiated: * to document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation. * to assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.


Eligibility criteria:
inclusion criteria: * patient is \>18 years of age (or minimum age as required by local regulation) * the patient has consented to participate by signing the "patient informed consent form" and/or has authorized the collection and release of his medical information by signing the "patient data release consent form". * the patient is suitable for implantation of one or more endeavor(tm) abt-578 eluting coronary stent system in one or more native artery target lesions. * lesion length and vessel diameter of the target lesion(s) are according to the "indications for use" as mentioned in the "instructions for use" that comes with every endeavor(tm) abt-578 eluting coronary stent system. * the patient is willing and able to cooperate with registry procedures and required follow up visits. exclusion criteria: * women with known pregnancy or who are lactating. * patients with hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, drugs such as abt-578, rapamycin, tacrolimus, sirolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media. * patients in whom anti-platelet and/pr anticoagulation therapy is contraindicated. * patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon. * current medical condition with a life expectancy of less than 12 months. * the subject is participating in another device or drug study. subject must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this trial. the subject may only be enrolled in this e-five registry once. * patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this registry.

Keywords: coronary artery disease drug-eluting stent
integrative medicine for hypermobility spectrum disorder and ehlers-danlos syndromes (imforhsdandeds)

Conditions: Ehlers-Danlos Syndrome; Hypermobile EDS (hEDS); Hypermobility Syndrome; EDS

Summary: a feasibility study of an integrative medicine program among patients with hypermobility spectrum disorder (hsd) or ehlers-danlos syndromes (eds)

the overall purpose of this study is to assess the feasibility of conducting a 9-week integrative medicine program that is comprised of a prescribed anti-inflammatory (mediterranean) diet, as well as general behavioral and psychosocial support among patients with hypermobility spectrum disorder (hsd) or ehlers-danlos syndromes (eds), in order to determine the recruitment potential in this population and to measure the ability of individuals to complete the program. participants will be prescribed a food plan, and adherence to and feasibility of the food plan will be measured through participant food tracking and a subjective assessment of the food plan in a brief satisfaction survey. this study aims to recruit 20 patients with hsd or eds and make preliminary observations regarding the effects of integrative medical care on pain reduction and improved quality of life.

Eligibility criteria:
inclusion criteria: * age 18-65 * beighton score of 4 or more to confirm joint hypermobility diagnosis * baseline vas score of 1 or more * not currently, or already a patient of dr. schaefer and healthy living community * ability to provide written informed consent * willingness to participate in 9-week integrative medicine intervention (and make dietary and lifestyle changes) * willingness to attend 1 in-person screening visit and 2 virtual office visits (or 3 virtual visits, if medical documentation of beighton score can be provided in advance of enrollment, and all other criteria are met) * access to an electronic device for myfitnesspal food-tracker use (i.e mobile device, tablet, laptop) exclusion criteria: * pregnant and lactating women, or planned pregnancy over the next 3 months * consumption of more than 14 (men) or 7 (women) alcoholic drinks per week * history of disordered eating or eating disorder * body mass index (bmi) considered underweight (\<18.5) * weight loss from metastatic cancer * unable to make dietary changes or participate in a 9-integrative medicine nutritional intervention * those with significant dietary changes, new medications, or new exercise routines within the past 90 days * currently, or already, a patient of dr. schaefer and healthy living community
alleviating trunk low back pain, with an active medical device study (atlas)

Conditions: Chronic Low Back Pain

Summary: the aim of the study is to evaluate the reduction of pain by wearing the atlas medical device in standardized daily activities for patients with chronic low back pain. this is an intervention al non blinded study with a crossover design comparing pain evaluated with an analogue visual scale with and without the atlas device during 5 standardized daily activities.

this study aims at assessing pain release by wearing a new medical device (atlas) in patients affected by chronic low back pain. population: patients with chronic low back pain admitted for a 4 weeks rehabilitation program. intervention: active rehabilitation and wearing the atlas device 60 min per day. the atlas study is carried out during the 5 first days of the rehabilitation program. primary outcome: pain intensity evaluation with a 100 mm visual analogue scale (vas) during 5 standardized activities (the most intensive pain during the 5 activities is recorded), with and without wearing the atlas device. secondary outcome measures: percentage of patients reporting pain decrease of at least 20 mm on the 100 mm vas during the 5 standardized activities with the atlas device compared without wearing the device. percentage of relieved patients (percentage of patient reporting pain intensity less than 30 mm on the 100 mm vas with wearing the device). pain intensity evaluated with the 100 mm vas before and after 60 min of wearing the atlas device. randomization: two groups (i.e. group a and b). primary outcome is evaluated at day 4 and 5, with a crossover design (group a: pain is evaluated during activities with the device at day 4 and without the device at day 5. group b: pain is evaluated during activities without the device at day 4 and with the device at day 5).

Eligibility criteria:
inclusion criteria: * chronic low back pain for more than 3 month * analogical visual scale superior or egal to 3/10 * bmi \< 30 * 18 \< age \< 75 years * patients who signed the informed consent * hospital anxiety and depression score less than 11 exclusion criteria: * - neurological or radicular deficit * skin pathology of the trunk region * antecedent of surgery of spinal fusion * implanted neurostimulation treatment * scoliosis with cobb angle \> 30° * history of vertebral fracture * bmi \> 30 * respiratory failure * recent rib fracture (less than 3 month) * pregnancy or breastfeeding * osteoporosis * refusal to participate to the study

Keywords: low back pain medical device spine rehabilitation traction
goal directed hemodynamic management and renal outcome after major non-cardiac surgery

Conditions: Major Non-cardiac Surgery

Summary: this study is designed to compare renal outcome of patients following major non-cardiac surgery with different perioperative hemodynamic managements: a goal directed hemodynamic management group (using picco) and a control group.

acute kidney injury (aki) is a common complication after major surgery. many studies showed that aki is associated with different complications: higher mortality, renal replacement therapy and prolonged hospital stay resulting in higher health care costs. until now just a few studies are published on prevention or therapy of aki after major surgery. most of these investigations are underpowered or show just marginal benefit. there are no studies published investigating the impact of goal-directed hemodynamic management on renal outcome following non-cardiac major surgery, even though hemodynamic stability seems to be of paramount importance for the kidneys. aim of this study is to investigate the impact of a goal directed hemodynamic management on renal outcome after major non-cardiac surgery. therefore patients will be randomized in one of two groups, the picco group with goal directed hemodynamic management and the control group, where picco data will be collected but will not influence hemodynamic management. in both groups the monitoring with transpulmonary thermodilution will be continued in the intensive care unit until 72 hours after surgery.

Eligibility criteria:
inclusion criteria: * elective major non-cardiac surgery lasting more than 3 hours with a following intensive care unit stay for more than 3 days: * gastrectomy * pancreas surgery * small bowel surgery * esophageal surgery * age ≥ 18 years * asa classification i to iii * written informed consent exclusion criteria: * need for dialysis * contraindications for an arterial line in the femoral artery: * stents * bypasses * severe peripheral artery occlusive disease * asa classification iv to v * pregnant woman

Keywords: major non-cardiac surgery, hemodynamic management, picco, acute kidney injury, renal outcome